Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer

First patient dosed in Phase I trial evaluating TG6050 15

Published 10 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Invir.IO, Press release, TG6050-en

Transgene’s Combined General Meeting of May 5, 2023

Transgene’s combined general meeting 15

Published 5 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio 15

Published 5 May 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

New Data Showing that Transgene and NEC’s TG4050 induces strong and specific immune responses against tumors presented at AACR 15

Published 18 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Preclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses 15

Published 17 April 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG6050-en

Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

Appointment of Carol Stuckley as New Independent Director 15

Published 12 April 2023
Categorized as 2023, dates, dates, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023

Availability of Preparatory documents for the combined general meeting of May 5, 2023 15

Published 11 April 2023
Categorized as 2023, dates, dates, Press release

Availability of Transgene’s 2022 Universal Registration Document

Availability of Transgene’s 2022 Universal Registration Document 15

Published 6 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers

Transgene to host KOL webinar on TG4050 15

Published 4 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings 15

Published 27 March 2023
Categorized as 2023, dates, dates, Press release

Posts pagination

Newer posts Page 1 … Page 10 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu